Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CELZ 
Creative Medical Technology Holdings Inc (CELZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/20/2024: CELZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.43% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/20/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.07M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 32085 | Beta 4.6 | 52 Weeks Range 1.92 - 6.90 | Updated Date 04/2/2025 |
52 Weeks Range 1.92 - 6.90 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.71 |
Earnings Date
Report Date 2025-03-20 | When After Market | Estimate -0.63 | Actual -1.12 |
Profitability
Profit Margin - | Operating Margin (TTM) -62857.8% |
Management Effectiveness
Return on Assets (TTM) -41.3% | Return on Equity (TTM) -65.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -868608 | Price to Sales(TTM) 461.07 |
Enterprise Value -868608 | Price to Sales(TTM) 461.07 | ||
Enterprise Value to Revenue 56.07 | Enterprise Value to EBITDA -1.45 | Shares Outstanding 2535900 | Shares Floating 1711659 |
Shares Outstanding 2535900 | Shares Floating 1711659 | ||
Percent Insiders 2.1 | Percent Institutions 14.86 |
Analyst Ratings
Rating 4 | Target Price 30 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Creative Medical Technology Holdings Inc
Company Overview
History and Background
Creative Medical Technology Holdings Inc. was founded to focus on biotechnology fields including urology, gynecology, and immunology and aims to improve patient care.
Core Business Areas
- Stem Cell Technology: Develops and commercializes stem cell therapies for various indications.
- Immunotherapy: Focuses on therapies that harness the immune system to fight diseases.
Leadership and Structure
Details regarding Creative Medical Technology Holdings Inc.'s leadership team and structure are not readily available from common sources. Further information is needed from company resources.
Top Products and Market Share
Key Offerings
- AmnioStem: AmnioStem is allogenic cell therapy for stroke. Specific market share data is not available. Competitors include companies developing stem cell therapies for neurological disorders.
- ImmCelz: A therapeutic cancer vaccine designed to combat various types of cancers. Market share data is not available. Competitors include companies developing cancer immunotherapies.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by rapid innovation, high R&D costs, and stringent regulatory oversight. Significant growth is driven by unmet medical needs and technological advances.
Positioning
Creative Medical Technology Holdings Inc. occupies a niche position within the biotech sector, focusing on stem cell and immunotherapy technologies. Its competitive advantage, if any, stems from the uniqueness and efficacy of its products, which requires clinical validation.
Total Addressable Market (TAM)
The TAM for cell therapies and immunotherapies is potentially billions of dollars. Creative Medical Technology Holdings Inc.'s position depends on successful clinical trials, regulatory approvals, and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary Technology Platforms
- Focus on Unmet Medical Needs
- Potential for Breakthrough Therapies
Weaknesses
- Limited Financial Resources
- Early Stage Development
- Reliance on Clinical Trial Success
- Lack of product marketing due to low funding
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Therapeutic Areas
- Accelerated Regulatory Pathways
- Rising demand for regenerative medicine
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Established Biotech Companies
- Patent Infringement
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- BMY
Competitive Landscape
Creative Medical Technology Holdings Inc. faces significant challenges competing with established biotech companies due to its limited resources and early stage development. It needs breakthrough research to become competitive.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends cannot be assessed without specific financial data.
Future Projections: Future growth projections require analyst estimates.
Recent Initiatives: Recent strategic initiatives require accessing company announcements and press releases.
Summary
Creative Medical Technology Holdings Inc. is a development-stage biotech company with proprietary technology platforms but faces financial constraints. Its success depends on positive clinical trial outcomes and securing partnerships. Threats include competition and regulatory hurdles; opportunities involve market expansion and accelerated regulatory pathways. The company is risky but has potential if it can get through clinical trials with positive results.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Publicly available information, SEC filings, press releases, and industry reports.
Disclaimers:
This analysis is based on limited publicly available information and is not financial advice. Market share are an estimate. Information is not guaranteed to be accurate or complete.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Creative Medical Technology Holdings Inc
Exchange NASDAQ | Headquaters Phoenix, AZ, United States | ||
IPO Launch date 2015-11-06 | Co-Founder, Chairman, President & CEO Mr. Timothy Warbington | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | |
Full time employees 4 | |||
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.